If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Mark Cooper AO is Professor of Diabetes and head of the Department of Diabetes within the Central Clinical School. His research and clinical interests are in diabetes and its complications, including kidney disease, heart disease and blindness.

Biography

Keywords

  • Diabetes
  • Diabetic Complications
  • kidney disease
  • heart disease
  • blindness

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2014 2025

Boosting the immune system to treat diabetic retinopathy

Wilkinson-Berka, J., Mackay, F., Cooper, M., Lim, L. L. P. & Wickremasinghe, S.

1/10/1730/09/20

Project: Research

A novel endogenous inhibitor for the treatment of diabetic nephropathy

Cooper, M. & Kantharidis, P.

1/01/1731/12/19

Project: Research

Research Output 1987 2019

Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus

Ohkuma, T., Jun, M., Rodgers, A., Cooper, M. E., Glasziou, P., Hamet, P., Harrap, S., Mancia, G., Marre, M., Neal, B., Perkovic, V., Poulter, N., Williams, B., Zoungas, S., Chalmers, J., Woodward, M. & on behalf of the ADVANCE Collaborative Group, 1 Jan 2019, In : Hypertension. 73, 1, p. 84-91 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File

A promising outlook for diabetic kidney disease

Cooper, M. & Warren, A. M., 1 Feb 2019, In : Nature Reviews Nephrology. 15, 2, p. 68-70 3 p.

Research output: Contribution to journalArticleOtherpeer-review

Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies

Warren, A. M., Knudsen, S. T. & Cooper, M. E., 23 May 2019, (Accepted/In press) In : Expert Opinion on Therapeutic Targets. p. 1-7 7 p.

Research output: Contribution to journalArticleOtherpeer-review

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults with Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial

Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., Zinman, B., Woerle, H. J., Baanstra, D., Pfarr, E., Schnaidt, S., Meinicke, T., George, J. T., Von Eynatten, M., McGuire, D. K. & for the CARMELINA Investigators, 1 Jan 2019, In : JAMA. 321, 1, p. 69-79 11 p.

Research output: Contribution to journalArticleResearchpeer-review

Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria

Cooper, M. E., Perkovic, V., Groop, P. H., Hocher, B., Hehnke, U., Meinicke, T., Koitka-Weber, A., van der Walt, S. & von Eynatten, M., 1 Jun 2019, In : Journal of hypertension. 37, 6, p. 1294-1300 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File